series	seriesDescription	geoAreaCode	geoAreaName	timePeriodStart	value	valueType	time_detail	upperBound	lowerBound	basePeriod	source	footnotes	Nature	Units	Reporting Type
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2010.0	17	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2011.0	71	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2012.0	94	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2013.0	90	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2014.0	86	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2015.0	81	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2016.0	84	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2017.0	84	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
